Fexofenadine
39 interactions 161 cited referencesFexofenadine is an antihistamine used to relieve allergy symptoms like sneezing, itchy eyes, hives, and itchy rash. Read the full Fexofenadine drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Fexofenadine Cabergoline Dostinex® Reduced efficacy of cabergoline and reduced efficacy of dopamine-2 receptors Details Fexofenadine Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Fexofenadine Darolutamide Nubeqa Increased exposure of OATP1B1 or OATP1B3 substrates Details Fexofenadine Apalutamide Erleada Reduced OATP1B1/P-gp substrates exposure Details Fexofenadine Apomorphine Apokyn Decreased apomorphine efficacy Details Fexofenadine Berotralstat Orladeyo Increased P-gp substrate exposure Details Fexofenadine Elexacaftor Increased OATP1B1/OATP1B3 substrate exposure Details Fexofenadine Eltrombopag Alvaiz Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details Fexofenadine Ensitrelvir Increased risk of P-gp substrate exposure Details Fexofenadine Epinephrine Reduced or reversal of EPINEPHrine pressor response Details Fexofenadine Foslevodopa Reduced efficacy of levodopa and an increased risk of exacerbating psychosis (or symptoms of Parkinson's disease: delusion, confus... Details Fexofenadine Itraconazole Sporanox Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Fexofenadine Lenacapavir Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Fexofenadine Leniolisib Joenja Increased OATP1B1/OATP1B3 substrate exposure Details Fexofenadine Levodopa Inbrija Reduced efficacy of levodopa and an increased risk of exacerbating psychosis (or symptoms of Parkinson's disease: delusion, confus... Details Fexofenadine Pitolisant Wakix Reduced efficacy of pitolisant Details Fexofenadine Simeprevir Olysio® Increased exposure of P-gp substrate Details Fexofenadine Venetoclax Venclexta Increased exposure of P-gp substrate and an increased toxicities of these substrates Details Fexofenadine Vimseltinib Romvimza Increased risk of P-gp substrate exposure Details Fexofenadine Voclosporin Lupkynis Increased OATP1B1/OATP1B3 substrate exposure Details Fexofenadine Lenacapavir Injection Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Fexofenadine Lenacapavir Oral Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Fexofenadine Levodopa Oral Inhalation Inbrija Reduced efficacy of levodopa and an increased risk of exacerbating psychosis (or symptoms of Parkinson's disease: delusion, confus... DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist